Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial
Age and Ageing · 2025
DOI: 10.1093/ageing/afaf276 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, 2025. Verfasst von Anita Nitchingham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Randwick Clinical Campus, University of New South Wales, Randwick, NSW, Australia. Hauptthemen laut MEDLINE: Delirium, Insulin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JJ Mason & HS Williams Memorial Fund, The Julia Lowy Foundation, Harry Triguboff Foundation.
Themen: Delir
Abstract (Originalsprache)
Background
Delirium affects up to 25% of hospitalised older patients; however, there are no effective pharmacological treatments. Accumulating evidence of brain insulin resistance and altered cerebral glucose metabolism during delirium present a promising therapeutic target.
Objective
To assess the safety and efficacy of intranasal insulin in the treatment of delirium.
Design
Single-centre, randomised, double-blind, placebo-controlled trial.
Setting
Two geriatric medicine wards in a tertiary hospital.
Participants
100 patients aged over 64 years presenting to hospital and admitted under geriatric medicine with delirium.
Interventions
Participants were randomised in a 1:1 ratio to receive 20 IU of long-acting insulin or placebo intranasally twice daily until delirium resolution, hospital discharge or intervention futility defined by prespecified criteria. Main outcome The primary outcome was delirium duration, assessed daily using the Confusion Assessment Method. Secondary outcomes included acute length of stay (LOS), delirium severity, antipsychotic use, hospital complications and mortality.
Results
The intention-to-treat analysis included 97 participants [intranasal insulin n = 48, control n = 49; mean (SD) age, 87.6 (7.0) years; 63% female]. Baseline characteristics were similar between groups. Median delirium duration [days (IQR)] was 4.8 [2.9, 9.2] for intranasal insulin and 6.8 [4.0, 9.8] for the control (HR 0.7, 95% CI 0.43–1.15; P = .16). Median acute LOS (days) was 7.9 [4.6, 14.5] for intranasal insulin and 12.9 [6.9, 16.8] for the control (HR 0.56, 0.35–0.89; P = .014). No significant differences were observed in other secondary outcomes. Intranasal insulin demonstrated favourable tolerability. Overall, 86% of the participants were compliant with the intervention (≥80% of doses). Prespecified subgroup analysis revealed an age-related response, with participants aged ≤88 years showing shorter delirium duration with intranasal insulin [n = 46; intranasal insulin: median 3.9 (IQR 2.9, 6.9) days vs control: 7.0 (4.7, 9.7); HR 0.34, 0.16–0.74; P = .006], whereas no difference was observed in participants aged >88 years [n = 51; intranasal insulin 5.4 (2.9, 11.1) vs control 4.9 (2.6, 12.9); HR 0.87, 0.39–1.94; P = .73]. Conclusion and relevance This is the first study of intranasal insulin for delirium treatment. The reduced LOS combined with the observed age-related effects warrants further investigation into the clinical potential of intranasal insulin in managing delirium in older patients.
Trial registration
ACTRN 12618000318280.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Randwick Clinical Campus, University of New South Wales, Randwick, NSW, Australia.
- Department of Geriatric Medicine, Prince of Wales Hospital and Community Health Services, Randwick, NSW, Australia.
- Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, NSW, Australia.
- School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia.
- School of Health Sciences, University of New South Wales, Sydney, NSW, Australia.
- Ageing Futures Institute, University of New South Wales, Sydney, NSW, Australia.
ORCID-Profile: Anita Nitchingham, Jacqueline C T Close, Lara Ann Harvey, Meera Agar
Förderung
- JJ Mason & HS Williams Memorial Fund
- The Julia Lowy Foundation
- Harry Triguboff Foundation
Zitieren
APA
Nitchingham, A., Close, J. C. T., Harvey, L. A., Taylor, M. E., Humburg, P., Tuch, B., Agar, M., & Caplan, G. A. (2025). Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial. Age and Ageing. https://doi.org/10.1093/ageing/afaf276
Vancouver
Nitchingham A, Close JCT, Harvey LA, Taylor ME, Humburg P, Tuch B, et al. Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial. Age and Ageing. 2025. doi:10.1093/ageing/afaf276
BibTeX
@article{Nitchingham2025,
author = {Nitchingham, Anita and Close, Jacqueline C T and Harvey, Lara Ann and Taylor, Morag E and Humburg, Peter and Tuch, Bernard and Agar, Meera and Caplan, Gideon A},
title = {Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial},
journal = {Age and Ageing},
year = {2025},
doi = {10.1093/ageing/afaf276}
}
EUVIMED